Medicine for treating chronic obstructive lung disease and preparation method thereof

Abstract

The invention discloses a drug, which contains purely natural traditional Chinese medicine for remedying the chronic obstructive pulmonary disease with the syndrome of qi deficiency of lung and kidney caused by the mutual obstruction of phlegm and stasis. The drug is a medical dosage which is prepared by the raw materials with the following weight portions of 2 to 8 portions of yam rhizomes, 4 to 8 portions of epimedium herbs, 8 portions of ephedra, 2 to 8 portions of bitter apricot nuts, 2 to 8 portions of magnolia officinals, 4 to 16 portions of danshen roots, 4 to 16 portions of dried milkvetch roots, 2 to 8 portions of gingers and 1 to 4 portions of liquorice roots. The drug of the invention has the functions of dispersing lung qi to send down the upward adverse flow of qi, eliminating phlegm, relieving dyspnea and reinforcing kidney to enhance the body resistance. The drug of the invention is applicable to the patient with the syndrome of qi deficiency of lung and kidney caused by the mutual obstruction of phlegm and stasis and has accurate and significant curative effect of remedying the chronic bronchitis with low recrudescence rate, and no adverse reaction occurs. The research of toxicology and pharmacodynamics completely testifies the safety of the drug of the invention and the wide pharmacological effects of the drug of the invention of relieving a cough, eliminating phlegm, relieving asthma, resisting inflammation etc. In addition, the invention also discloses the preparation method of the drug.

Description

technical field [0001] The invention relates to a medicine containing pure natural traditional Chinese medicine for treating chronic obstructive pulmonary disease (phlegm and blood stasis mutual obstruction, lung-kidney qi deficiency syndrome); in addition, the invention also relates to a preparation method of the medicine. Background technique [0002] Chronic obstructive pulmonary disease (COPD) is a disease characterized by airflow limitation, which generally refers to chronic bronchitis and / or emphysema with airflow limitation. [0003] Obstructive emphysema is caused by the stimulation of harmful factors such as smoking, infection, and air pollution, which causes the airway elasticity at the distal end of the terminal bronchiole to decrease, excessive inflation, inflation and lung volume, accompanied by destruction of the airway wall. The pathogenesis of emphysema has not been fully elucidated so far, and it is generally believed that it is formed by the synergistic eff...

AI Technical Summary

Problems solved by technology

(3) None of the existing drugs for the treatment of COPD can alleviate the downward trend of lung function, so the drug treatment of COPD is mainly to improve symptoms and reduce complications

(6) Regular inhaled corticosteroid therapy is only applicable to COPD patients who are effective to glucocorticoid therapy and have symptoms and confirmed by pulmonary function tests; or FEV1<50% predicted value, symptoms repeatedly aggravated, and antibiotics and / or or oral glucocorticoid therapy

[0015] ② α1-AT supplementation therapy: only for patients with severe α1-AT deficiency and emphysema, but it is expensive and not recommended for COPD patients unrelated to α1-AT deficiency

[0017] ④ Mucolytic agents: Although a small number of patients are effective in the treatment of mucolytic agents, the overall benefit is less, so it is not recommended to be widely used

[0018] ⑤Antioxidant: N-acetylcysteine ​​can reduce the number of acute exacerbations of COPD, and is effective in treating patients with recurrent acute exacerbations, but further clinical evaluation is needed

[0019] ⑥ Immunomodulators: Immunostimulants can reduce the severity of acute exacerbations, but they cannot be recommended for routine use according to the available data

[0027] (2) The main causes of acute exacerbation are trachea, bronchial infection and air pollution, but the cause of acute exacerbation of about 1 / 3 patients is difficult to find;

[0035] (3) Glucocorticoids: When COPD is acutely exacerbated, in addition to bronchodilators (plus antibiotics and oxygen therapy), oral or intravenous glucocorticoids are recommended. It is not yet clear what the correct dose should be given, and large doses will increase significantly side effect

[0041] Currently used drugs, including Chinese invention patents CN1281360A January 24, 2001, CN1607940A April 20, 2005, CN1633295A June 29, 2005, CN1713914A December 28, 2005, adrenergic agonists, anticholinergics , theophylline, glucocorticosteroids and mucus motility or expectorant medicines are all western medicines, although these western medicines have certain curative effect, the phenomenon of its toxic and side effects is also more serious, and the therapeutic effect is also limited; existing compound Chinese medicine preparation or soup Therapeutic effect of the drug is also limited, and has little effect on the prevention of COPD progression and disease exacerbation

Images